Sparano JA (2000) Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer 1(1):32–40 discussion 1–2

Article  CAS  PubMed  Google Scholar 

Schrijvers D, Vermorken JB (2005) Taxanes in head and neck cancer. Future Oncol 1(6):829–839

Article  CAS  PubMed  Google Scholar 

Van Cutsem E (2004) The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Oncologist 9(Suppl 2):9–15

Article  PubMed  Google Scholar 

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512

Article  CAS  PubMed  Google Scholar 

Reck M, Kaiser R, Mellemgaard A, Douillard J-Y, Orlov S, Krzakowski M et al (2014) Docetaxel plus Nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15(2):143–155

Article  CAS  PubMed  Google Scholar 

Malingre MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Ten Bokkel Huinink WW et al (2001) Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 19(4):1160–1166

Article  CAS  PubMed  Google Scholar 

Oostendorp RL, Huitema A, Rosing H, Jansen RS, Ter Heine R, Keessen M et al (2009) Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clin Cancer Res 15(12):4228–4233

Article  CAS  PubMed  Google Scholar 

Schwartzberg LS, Navari RM (2018) Safety of Polysorbate 80 in the oncology setting. Adv Ther 35(6):754–767

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15(1):110–115

Article  CAS  PubMed  Google Scholar 

Sohi GK, Levy J, Delibasic V, Davis L, Mahar A, Amirazodi E et al (2020) The cost of chemotherapy administration: a systematic review and meta-analysis. American Society of Clinical Oncology

Sohail MF, Rehman M, Sarwar HS, Naveed S, Salman O, Bukhari NI et al (2018) Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends. Int J Nanomed 13:3145

Article  CAS  Google Scholar 

Helgason H, Kruijtzer C, Huitema A, Marcus S, ten Bokkel Huinink W, Schot M et al (2006) Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. Br J Cancer 95(7):794–800

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smolinski MP, Urgaonkar S, Pitzonka L, Cutler M, Lee G, Suh KH et al (2021) Discovery of encequidar, first-in-class intestine specific P-glycoprotein inhibitor. J Med Chem 64(7):3677–3693

Article  CAS  PubMed  Google Scholar 

Kim TE, Gu N, Yoon SH, Cho JY, Park KM, Shin SG et al (2012) Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies. Clin Ther 34(2):482–494

Article  CAS  PubMed  Google Scholar 

Rugo HS, Umanzor GA, Barrios FJ, Vasallo RH, Chivalan MA, Bejarano S et al (2023) Open-label, randomized, multicenter, phase III study comparing oral paclitaxel plus encequidar versus intravenous paclitaxel in patients with metastatic breast cancer. J Clin Oncol 41(1):65–74

Article  CAS  PubMed  Google Scholar 

Gabrielsson J, Weiner D (2012) Non-compartmental analysis. Methods Mol Biol 929:377–389

Article  CAS  PubMed  Google Scholar 

Jackson CG, Hung T, Segelov E, Barlow P, Prenen H, McLaren B et al (2021) Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: a randomised crossover pharmacokinetic study. Br J Clin Pharmacol 87(12):4670–4680

Article  CAS  PubMed  Google Scholar 

He J, Jackson CG, Deva S, Hung T, Clarke K, Segelov E et al (2022) Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors. CPT: Pharmacometrics Syst Pharmacol 11(7):867–879

CAS  PubMed  Google Scholar 

Dai M-S, Chao T-C, Chiu C-F, Lu Y-S, Shiah H-S, Jackson CG et al (2023) Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study. Therapeutic Adv Med Oncol 15:17588359231183680

Article  CAS  Google Scholar 

Baker SD, Li J, ten Tije AJ, Figg WD, Graveland W, Verweij J et al (2005) Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 77(1):43–53

Article  CAS  PubMed  Google Scholar